Sorrento Therapeutics

Sorrento, NantBioScience form joint venture

Friday, July 10, 2015

Sorrento Therapeutics, a clinical stage oncology company, and NantBioScience, a majority owned subsidiary of NantWorks, have established a joint venture to focus on the development of first-in-class small molecules addressing drivers of cancer growth, including cancer stem cells. ‎Sorrento will contribute key small molecule programs (lead inhibitors of the proto-oncogenes c-Myc, and the master metabolism regulator HIF-1 alpha, and an inducer of the tumor suppressor cytokine TRAIL) to the joint venture, which will be 60% owned by NantBioScience and 40% owned by Sorrento, and funded accordingly.

[Read More]

NantWorks, Sorrento collaborate on novel anti-cancer immunotherapies

Wednesday, March 18, 2015

NantWorks, an umbrella organization developing of next generation diagnostics and therapeutics, and Sorrento Therapeutics, an oncology company, have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento’s proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks’ proprietary pan-omics based, precision medicine approach.

[Read More]

Sorrento awarded up to $2.6M from NIH for bispecific antibodies

Wednesday, July 9, 2014

Sorrento Therapeutics, a late-stage clinical oncology company developing new treatments for cancer and its associated pain, has received two NIH small business grants, which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento’s highly diverse, fully human G-MAB library and proprietary antibody conjugation technology platforms have broad applications beyond oncology, including other therapeutic areas such as anti-infectives and auto-immune diseases.

[Read More]

Sorrento Therapeutics completes IgDraSol merger

Wednesday, September 11, 2013

Sorrento Therapeutics has completed its merger with Igdrasol, a privately-held company focused on the development of cancer therapeutics. Igdrasol shareholders will receive the equivalent of 3,047,968 million shares of Sorrento’s common stock. Reflecting Sorrento’s recent reverse stock split, and based on the closing share price on Sept. 6, 2013, the transaction is valued at $28.2 million.

[Read More]

Sorrento Therapeutics licenses Biomiga Diagnostics’ drug monitoring device

Wednesday, September 11, 2013

Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, has secured an exclusive license for the worldwide rights to Biomiga Diagnostics‘ proprietary therapeutic drug monitoring (TDM) device for paclitaxel products. The agreement allows Sorrento to utilize the TDM device for the clinical development of individualized dosing regimens of Sorrento’s late-stage compound, Cynviloq (paclitaxel polymeric micelle).

[Read More]

Sorrento, BGN Technologies collaborate on Hepatitis C

Wednesday, July 17, 2013

Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, and BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, have entered into an option and license agreement covering several anti-Hepatitis C Virus (HCV) antibody clones identified from patients who have recovered from HCV infections. Sorrento plans to develop these early findings into a potential therapeutic product.

[Read More]